Pyomyositis is a tropical infection affecting skeletal muscles manifesting as high-grade fever with pain in the affected limbs usually caused by Gram-positive microorganisms. Gram-negative organisms causing pyomyositis is uncommon but has been reported. Burkholderia cepacia is a Gram-negative nonfermenter causing opportunistic infections in immunocompromised patients, has been reported to cause pyomyositis only once before. We report a case of B. cepacia pyomyositis in a patient with no history of immunocompromised status, manifesting as disseminated infection with hemophagocytic syndrome presenting to our intensive care unit.
Chiedozi LC. Pyomyositis. Review of 205 cases in 112 patients. Am J Surg 1979;137:255-9.
Walling DM, Kaelin WG Jr. Pyomyositis in patients with diabetes mellitus. Rev Infect Dis 1991;13:797-802.
Gousseff M, Lanternier F, Ferroni A, Chandesris O, Mahlaoui N, Hermine O, et al. Enterobacter cloacae pyomyositis complicating chronic granulomatous disease and review of Gram-negative bacilli pyomyositis. Eur J Clin Microbiol Infect Dis 2013;32:729-34.
El-Laboudi AH, Etherington C, Whitaker P, Clifton IJ, Conway SP, Denton M, et al. Acute Burkholderia cenocepacia pyomyositis in a patient with cystic fibrosis. J Cyst Fibros 2009;8:273-5.
Liao CH, Chang HT, Lai CC, Huang YT, Hsu MS, Liu CY, et al. Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an Intensive Care Unit. Diagn Microbiol Infect Dis 2011;70:260-6.
Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: Beyond Pseudomonas and Acinetobacter. Indian J Med Microbiol 2011;29:4-12.
Miller NJ, Duncan RD, Huntley JS. The conservative management of primary pyomyositis abscess in children: Case series and review of the literature. Scott Med J 2011;56:i-181.
Brown GR. Cotrimoxazole – Optimal dosing in the critically ill. Ann Intensive Care 2014;4:13.
Batra P, Deo V, Mathur P, Gupta AK. Cotrimoxazole, a wonder drug in the era of multiresistance: Case report and review of literature. J Lab Physicians 2017;9:210-3.